Looking to sell Upstream Bio stock or options?
Contact usUpstream Bio, a biotech company operator, is designed to tackle allergic and inflammatory diseases. Their flagship program is a monoclonal antibody in the clinical-stage that hinders the TSLP receptor. This receptor is a verified target situated upstream of numerous signaling pathways that impact a range of immune cells crucial to both common and rare diseases. This enables healthcare professionals to alleviate the impact of inflammatory and allergic diseases on patients with innovative therapeutics.
Maruho, Access Biotechnology, Bain Capital Life Sciences, Samsara BioCapital, Wellington Management, HBM Partners, TCG Crossover Management, Altshuler Shaham Investment House, OrbiMed, Enavate Sciences, HBM Healthcare Investments, Venrock, Omega Funds, Decheng Capital.